Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMGO2MC)

• Drug Name: FENOFIBRIC ACID Drug Info
• Synonyms: Fenofibric acid; 42017-89-0; Procetofenic acid; 2-(4-(4-Chlorobenzoyl)phenoxy)-2-methylpropanoic acid; alpha 1081; NSC 281318; LF 178 acid; UNII-BGF9MN2HU1; 2-[4-(4-chlorobenzoyl)phenoxy]-2-methylpropanoic acid; LF 153; FNF Acid; C17H15ClO4; Trilipix; CCRIS 7302; EINECS 255-626-9; BGF9MN2HU1; CHEMBL981; BRN 2058973; CHEBI:83469; 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropionic Acid; Propanoic acid, 2-(4-(4-chlorobenzoyl)phenoxy)-2-methyl-; AK117112; 2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoic acid; W-106287

Indication

Disease Entry	ICD 11	Status	REF
Cardiovascular disease	BA00-BE2Z	Approved	[1]

• Cross-matching ID:
  PubChem CID: 64929
  ChEBI ID: CHEBI:83469
  CAS Number: CAS 42017-89-0
  TTD Drug ID: DMGO2MC
  VARIDT Drug ID: DR00651
  INTEDE Drug ID: DR2500
  ACDINA Drug ID: D00269

Molecule-Related Drug Atlas

Drug(s) Targeting Fatty acid-binding protein 1 (FABP1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
INDOPROFEN	DM5QSKN	Gout	FA25	Withdrawn from market	[2]
OLEIC ACID	DM54O1Z	Discovery agent	N.A.	Investigative	[2]
1-anilinonaphthalene-8-sulfonic acid	DMNGY0E	N. A.	N. A.	Investigative	[2]

Drug(s) Transported By ATP-binding cassette sub-family A member 1 (ABCA1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cholesterol	DMR3J6S	Discovery agent	N.A.	Investigative	[5]

Drug(s) Metabolized By NADPH-dependent carbonyl reductase 1 (CBR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Menadione	DMSJDTY	Vitamin K deficiency	5B59	Approved	[6]
Daunorubicin	DMQUSBT	Acute monocytic leukemia		Approved	[7]
PGF2alpha	DM4XAU7	Solid tumour/cancer	2A00-2F9Z	Clinical trial	[8]
VUFB-11502	DM7WFR0	N. A.	N. A.	Preclinical	[9]
Phenanthrene-9,10-dione	DMG8KS9	Discovery agent	N.A.	Investigative	[10]
BRN-3548355	DM4KXT0	N. A.	N. A.	Investigative	[11]

Drug(s) Metabolized By Aldo-keto reductase 1B1 (AKR1B1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Allopregnanolone	DMNLHAC	Depression	6A70-6A7Z	approved	[12]

Drug(s) Metabolized By Aldo-keto reductase 1C3 (AKR1C3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[13]
ANDROSTERONE	DMITJAK	N. A.	N. A.	Phase 3	[14]
Trastuzumab emtansine	DMU1LXS	HER2-positive breast cancer	2C60-2C65	Phase 2	[15]
4-oxo-nonenal	DMPX1J9	Discovery agent	N.A.	Investigative	[16]
Acenaphthenol	DMT3QYZ	N. A.	N. A.	Investigative	[14]
Indan-1-ol	DMMLQZJ	N. A.	N. A.	Investigative	[14]

Drug(s) Metabolized By Aldo-keto reductase 1C1 (AKR1C1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Progesterone	DMUY35B	Amenorrhea	GA20.0	Approved	[17]
Nabumetone	DMAT2XH	Osteoarthritis	FA00-FA05	Approved	[18]
Dihydrotestosterone	DM3S8XC	Prostate hyperplasia	GA90	Phase 4	[17]
Trastuzumab emtansine	DMU1LXS	HER2-positive breast cancer	2C60-2C65	Phase 2	[15]
BRN-3548355	DM4KXT0	N. A.	N. A.	Investigative	[11]

Drug(s) Metabolized By Aldo-keto reductase 1C2 (AKR1C2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trastuzumab emtansine	DMU1LXS	HER2-positive breast cancer	2C60-2C65	Phase 2	[15]
BRN-3548355	DM4KXT0	N. A.	N. A.	Investigative	[11]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Fatty acid-binding protein 1 (FABP1)	TTIV96N	FABPL_HUMAN	Inhibitor	[2]

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
ATP-binding cassette sub-family A member 1 (ABCA1)	DT61TWI	ABCA1_HUMAN	Substrate	[3]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Aldo-keto reductase 1C3 (AKR1C3)	DEGQTXO	AK1C3_HUMAN	Substrate	[4]
NADPH-dependent carbonyl reductase 1 (CBR1)	DE9JFMC	CBR1_HUMAN	Substrate	[4]
Aldo-keto reductase 1C1 (AKR1C1)	DE7P2FB	AK1C1_HUMAN	Substrate	[4]
Aldo-keto reductase 1C2 (AKR1C2)	DEOY5ZM	AK1C2_HUMAN	Substrate	[4]
Aldo-keto reductase 1B1 (AKR1B1)	DE7WS3H	ALDR_HUMAN	Substrate	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2662).
• [2] Characterization of the drug binding specificity of rat liver fatty acid binding protein. J Med Chem. 2008 Jul 10;51(13):3755-64.
• [3] Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner. Arterioscler Thromb Vasc Biol. 2005 Jun;25(6):1193-7.
• [4] In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8.
• [5] ABCA1 redistributes membrane cholesterol independent of apolipoprotein interactions. J Lipid Res. 2003 Jul;44(7):1373-80.
• [6] Polycyclic aromatic hydrocarbon quinones and glutathione thioethers as substrates and inhibitors of the human placental NADP-linked 15-hydroxyprostaglandin dehydrogenase. J Biol Chem. 1987 Sep 15;262(26):12448-51.
• [7] Flavonoids as inhibitors of human carbonyl reductase 1. Chem Biol Interact. 2008 Jul 30;174(2):98-108.
• [8] Metabolism of prostaglandins by the nonpregnant human uterus. J Clin Endocrinol Metab. 1983 Apr;56(4):678-85.
• [9] The critical role of oxidative stress in the toxicity and metabolism of quinoxaline 1,4-di-N-oxides in vitro and in vivo. Drug Metab Rev. 2016 May;48(2):159-82.
• [10] Studies on reduction of S-nitrosoglutathione by human carbonyl reductases 1 and 3. Chem Biol Interact. 2011 May 30;191(1-3):95-103.
• [11] Characterization of enzymes participating in carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone (NNK) in human placenta. Chem Biol Interact. 2001 Jan 30;130-132(1-3):737-48.
• [12] FDA Label of Brexanolone. The 2020 official website of the U.S. Food and Drug Administration.
• [13] Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. Toxicol Lett. 2008 Sep;181(1):1-6.
• [14] Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7, 8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione. Biochemistry. 1998 May 12;37(19):6781-90.
• [15] The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact. 2014 Sep 5;220:241-7.
• [16] Instability of C154Y variant of aldo-keto reductase 1C3. Chem Biol Interact. 2017 Oct 1;276:194-202.
• [17] Human 3-alpha hydroxysteroid dehydrogenase type 3 (3alpha-HSD3): the V54L mutation restricting the steroid alternative binding and enhancing the 20alpha-HSD activity. J Steroid Biochem Mol Biol. 2014 May;141:135-43.
• [18] Reductive metabolism of nabumetone by human liver microsomal and cytosolic fractions: exploratory prediction using inhibitors and substrates as marker probes. Eur J Drug Metab Pharmacokinet. 2015 Jun;40(2):127-35.